Genmab A/S (NASDAQ:GMAB) Given Consensus Rating of “Moderate Buy” by Analysts

Genmab A/S (NASDAQ:GMAB) has been given an average rating of “Moderate Buy” by the thirteen research firms that are presently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation, eight have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $39.17.

Several research firms have recently commented on GMAB. Leerink Partnrs raised Genmab A/S from a “hold” rating to a “strong-buy” rating in a research note on Thursday, February 13th. William Blair raised shares of Genmab A/S from a “market perform” rating to an “outperform” rating in a report on Tuesday, March 11th. Wall Street Zen cut shares of Genmab A/S from a “buy” rating to a “hold” rating in a research note on Friday, June 6th. Leerink Partners upgraded shares of Genmab A/S from a “market perform” rating to an “outperform” rating and set a $27.00 price target for the company in a research report on Thursday, February 13th. Finally, Truist Financial reduced their price objective on shares of Genmab A/S from $50.00 to $45.00 and set a “buy” rating for the company in a research note on Tuesday, March 11th.

Institutional Trading of Genmab A/S

Institutional investors and hedge funds have recently bought and sold shares of the stock. Rhumbline Advisers grew its position in shares of Genmab A/S by 3.2% during the first quarter. Rhumbline Advisers now owns 16,956 shares of the company’s stock valued at $332,000 after purchasing an additional 532 shares in the last quarter. Foresight Group Ltd Liability Partnership bought a new position in Genmab A/S during the first quarter valued at approximately $954,000. Scientech Research LLC boosted its stake in Genmab A/S by 209.5% during the first quarter. Scientech Research LLC now owns 34,611 shares of the company’s stock valued at $678,000 after buying an additional 23,428 shares during the last quarter. Cubist Systematic Strategies LLC grew its holdings in Genmab A/S by 112.4% during the 1st quarter. Cubist Systematic Strategies LLC now owns 1,258,143 shares of the company’s stock valued at $24,634,000 after buying an additional 665,893 shares in the last quarter. Finally, Graham Capital Management L.P. grew its holdings in Genmab A/S by 28.9% during the 1st quarter. Graham Capital Management L.P. now owns 71,452 shares of the company’s stock valued at $1,399,000 after buying an additional 16,035 shares in the last quarter. 7.07% of the stock is currently owned by institutional investors.

Genmab A/S Trading Up 2.0%

Shares of GMAB stock opened at $23.09 on Friday. Genmab A/S has a 12 month low of $17.24 and a 12 month high of $28.56. The stock has a market cap of $14.81 billion, a P/E ratio of 13.27, a P/E/G ratio of 2.65 and a beta of 0.96. The company has a 50 day simple moving average of $20.46 and a two-hundred day simple moving average of $20.73.

Genmab A/S (NASDAQ:GMAB) last posted its quarterly earnings data on Thursday, May 8th. The company reported $0.31 EPS for the quarter, topping the consensus estimate of $0.23 by $0.08. Genmab A/S had a return on equity of 16.78% and a net margin of 36.30%. The firm had revenue of $715.00 million during the quarter, compared to analyst estimates of $5.17 billion. As a group, equities analysts forecast that Genmab A/S will post 1.45 earnings per share for the current year.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.